A KRAS Inhibitor in Participants With Advanced Solid Tumors
brief summary
This is a Phase 1/2, open-label, multi-center study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-929 in participants with advanced solid tumors harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
detailed description
Part A will evaluate escalating doses of ETX-929 as monotherapy in participants with advanced solid tumors. Part B will evaluate escalating doses of ETX-929 as combination therapy with fixed dose cetuximab in participants. Part C and Part D will expand enrollment of ETX-929 as monotherapy and in combination with cetuximab at the recommended doses from escalation.
Each study part will include a 28-day screening period, followed by treatment with ETX-929 monotherapy or combination therapy.
official title
A Phase 1/2, First-in-Human Study of ETX-929, a Pan-KRAS Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With KRAS-Altered Advanced Solid Tumors